SCHEMBL5234368

SCHEMBL5234368

Cc1cc(C)c(S(=O)(=O)O)c(C)c1.N[n+]1cccc(-c2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ MCOLN3 Q8TDD5 1/20 0.41
▸ HTT P42858 3/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP8 P22894 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ RECQL P46063 1/20 0.38
▸ F2 P00734 2/20 0.36
▸ PRSS1 P07477 2/20 0.36
▸ PRSS2 P07478 2/20 0.36
▸ PRSS3 P35030 2/20 0.36
▸ KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236783 0.89 LMNA (0.43) LMNASMN1; SMN2MCOLN3HTTRAB9A
SCHEMBL5234362 0.86 LMNA (0.41) LMNASMN1; SMN2MCOLN3HTTRAB9A
SCHEMBL28785424 0.83 F2 (0.37) HTTRAB9ACA1CA2MMP1
SCHEMBL5230088 0.82 RAPGEF4 (0.42) LMNASMN1; SMN2HTTRAB9AL3MBTL1
SCHEMBL5232759 0.81 RAPGEF4 (0.38) SMN1; SMN2CA1CA2MMP1MMP2
SCHEMBL5230249 0.76 TCF4 (0.38) LMNASMN1; SMN2HTTRAB9ACA1
SCHEMBL5235759 0.74 LMNA (0.45) LMNASMN1; SMN2HTTRAB9ACA1
SCHEMBL5236778 0.74 LMNA (0.43) LMNASMN1; SMN2MCOLN3HTTRAB9A
SCHEMBL28521918 0.73 F2 (0.36) LMNASMN1; SMN2MCOLN3HTTCA1
Hydroxyamine SCHEMBL259333 0.73 CA1 (0.54) LMNARAB9ACA1CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 — — EP disclosed
Send feedback